Suppr超能文献

流感血凝素和神经氨酸酶:协同进化以逃避免疫的阴阳蛋白。

Influenza Hemagglutinin and Neuraminidase: Yin⁻Yang Proteins Coevolving to Thwart Immunity.

机构信息

Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD 20892, USA.

出版信息

Viruses. 2019 Apr 16;11(4):346. doi: 10.3390/v11040346.

Abstract

Influenza A virions possess two surface glycoproteins-the hemagglutinin (HA) and neuraminidase (NA)-which exert opposite functions. HA attaches virions to cells by binding to terminal sialic acid residues on glycoproteins/glycolipids to initiate the infectious cycle, while NA cleaves terminal sialic acids, releasing virions to complete the infectious cycle. Antibodies specific for HA or NA can protect experimental animals from IAV pathogenesis and drive antigenic variation in their target epitopes that impairs vaccine effectiveness in humans. Here, we review progress in understanding HA/NA co-evolution as each acquires epistatic mutations to restore viral fitness to mutants selected in the other protein by host innate or adaptive immune pressure. We also discuss recent exciting findings that antibodies to HA can function in vivo by blocking NA enzyme activity to prevent nascent virion release and enhance Fc receptor-based activation of innate immune cells.

摘要

甲型流感病毒粒子拥有两种表面糖蛋白——血凝素(HA)和神经氨酸酶(NA)——它们发挥着相反的作用。HA 通过与糖蛋白/糖脂上的末端唾液酸残基结合将病毒粒子附着到细胞上,从而启动感染周期,而 NA 则切割末端唾液酸,释放病毒粒子以完成感染周期。针对 HA 或 NA 的抗体可以保护实验动物免受 IAV 发病机制的影响,并在其靶表位上驱动抗原变异,从而降低疫苗在人类中的有效性。在这里,我们回顾了对 HA/NA 共同进化的理解进展,因为每种蛋白都会获得上位突变,以恢复在另一种蛋白中被宿主固有或适应性免疫压力选择的突变体的病毒适应性。我们还讨论了最近令人兴奋的发现,即针对 HA 的抗体可以通过阻断 NA 酶活性在体内发挥作用,从而阻止新形成的病毒粒子释放,并增强基于 Fc 受体的先天免疫细胞激活。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7282/6520700/d256ab0927f4/viruses-11-00346-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验